OMERS ADMINISTRATION Corp Invests $372,000 in Rezolute, Inc. (NASDAQ:RZLT)

OMERS ADMINISTRATION Corp bought a new position in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 76,000 shares of the company's stock, valued at approximately $372,000. OMERS ADMINISTRATION Corp owned approximately 0.13% of Rezolute as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Nantahala Capital Management LLC lifted its holdings in shares of Rezolute by 10.9% during the fourth quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock worth $14,004,000 after buying an additional 280,861 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Rezolute by 699.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company's stock worth $12,377,000 after buying an additional 2,210,038 shares in the last quarter. Susquehanna International Group LLP lifted its holdings in shares of Rezolute by 749.0% during the fourth quarter. Susquehanna International Group LLP now owns 893,601 shares of the company's stock worth $4,379,000 after buying an additional 788,349 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Rezolute by 19.8% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,223 shares of the company's stock worth $2,578,000 after buying an additional 86,990 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Rezolute by 5.2% during the fourth quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock worth $2,535,000 after buying an additional 25,413 shares in the last quarter. Institutional investors and hedge funds own 82.97% of the company's stock.

Analysts Set New Price Targets

RZLT has been the subject of a number of research reports. Wedbush reissued an "outperform" rating and set a $12.00 target price on shares of Rezolute in a report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 price target on shares of Rezolute in a research note on Monday, April 28th. JMP Securities boosted their price target on Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research note on Thursday, February 13th. Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a research note on Monday, February 10th. Finally, Craig Hallum raised Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Rezolute currently has an average rating of "Buy" and a consensus target price of $12.14.

Rezolute Stock Up 6.4%

Rezolute stock opened at $3.80 on Tuesday. Rezolute, Inc. has a 12-month low of $2.22 and a 12-month high of $6.19. The business's 50-day moving average price is $3.24 and its two-hundred day moving average price is $4.28. The stock has a market cap of $230.03 million, a PE ratio of -3.11 and a beta of 1.01.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). As a group, analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Insider Buying and Selling at Rezolute

In other Rezolute news, CFO Daron Evans bought 10,000 shares of the firm's stock in a transaction on Wednesday, March 26th. The shares were purchased at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the transaction, the chief financial officer now directly owns 237,900 shares in the company, valued at approximately $687,531. The trade was a 4.39% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Nevan C. Elam bought 12,302 shares of the firm's stock in a transaction on Thursday, March 27th. The stock was acquired at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the transaction, the chief executive officer now owns 224,119 shares of the company's stock, valued at approximately $638,739.15. The trade was a 5.81% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 29,060 shares of company stock worth $83,694 over the last 90 days. Insiders own 18.39% of the company's stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

Want to see what other hedge funds are holding RZLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rezolute, Inc. (NASDAQ:RZLT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.